Abstract 3260: The preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation
Sign Up to like & getrecommendations! Published in 2020 at "Immunology"
DOI: 10.1158/1538-7445.am2020-3260
Abstract: CS1001 is a high-affinity, fully human programmed death ligand-1 (PD-L1) blocking IgG4 monoclonal antibody. So far three therapeutic anti-PD-L1 antibodies (atezolizumab, avelumab, durvalumab) have been approved by US FDA in different cancer indications. CS1001 selectively… read more here.
Keywords: cs1001; igg4 monoclonal; antibody; anti ... See more keywords